Alvotech completes $137 million private placement
Alvotech has completed a private placement of approximately USD 137 million. The private placement was directed solely to eligible and professional investors in Iceland, including pension funds. Alvotech is a biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and was the first Icelandic company to be dual listed in the U.S. and Iceland.
BBA//Fjeldco was Alvotech’s legal advisor with respect to the private placement and congratulates its management team and employees on the achievement.

Alvotech has completed a private placement of approximately USD 137 million. The private placement was directed solely to eligible and professional investors in Iceland, including pension funds. Alvotech is a biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and was the first Icelandic company to be dual listed in the U.S. and Iceland.
BBA//Fjeldco was Alvotech’s legal advisor with respect to the private placement and congratulates its management team and employees on the achievement.
Alvotech has completed a private placement of approximately USD 137 million. The private placement was directed solely to eligible and professional investors in Iceland, including pension funds. Alvotech is a biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and was the first Icelandic company to be dual listed in the U.S. and Iceland.
BBA//Fjeldco was Alvotech’s legal advisor with respect to the private placement and congratulates its management team and employees on the achievement.